When the Ebola Headline Hits: What I’m Actually Watching

When the Ebola Headline Hits: What I’m Actually Watching

By Aaron Asay, PA-C, DMSc

You saw the headline. Maybe it came up in your news feed this morning, or someone in a group chat sent it with a string of question marks. WHO has declared a public health emergency. JFK is screening flights from affected countries. And the question running through your head, whether you say it out loud or not, is: Is this going to be like COVID?

I understand that feeling. I’ve spent 25 years responding to outbreaks, disasters, and health crises, and I’ve watched what the first wave of media coverage does to people — it creates anxiety without context, and anxiety without context is where bad decisions get made. So let me give you what most of those headlines are leaving out.

What’s actually happening in 2026

WHO declared a public health emergency of international concern in May. Major US airports including JFK have begun screening travelers arriving from affected regions in the DRC. The outbreak is real, it is serious, and international responders are working on it.

The strain driving the 2026 outbreak is Bundibugyo virus — a distinct Ebola species from Zaire ebolavirus, which is the strain most people picture when they hear “Ebola.” That distinction matters more than it might seem. The vaccine you may have heard about — Ervebo, licensed in the US in 2019 — works against Zaire ebolavirus. It does not work against Bundibugyo. There is no licensed vaccine for Bundibugyo, no approved monoclonal antibody product, and no specific antiviral. The international response looks different this time, and understanding why helps you hold the news accurately rather than just anxiously.

Bundibugyo has caused two previous outbreaks: Uganda in 2007 and DRC in 2012. Neither received significant US media coverage, and neither crossed into the United States. That track record is relevant context for what you’re deciding to pay attention to right now.

What CDC is and isn’t saying

CDC currently assesses the risk to Americans as low. But the part most headlines skip is the next sentence: travel from an affected country is not by itself an epidemiologic risk factor.

That phrase is doing a lot of work. If a coworker traveled to the DRC last month, that travel alone doesn’t place you at risk. If your kid’s friend has a parent who just returned from an affected region, that also doesn’t create exposure. The Ebola transmission pathway is specific: direct contact with the body fluids of a symptomatic person, or with surfaces and objects contaminated by them. The groups who carry real exposure risk are healthcare workers, burial team members, laboratory workers, and household caregivers of sick patients — not casual contacts, not fellow plane passengers, not the neighbor whose cousin lives near Kinshasa.

Knowing this doesn’t mean you dismiss the outbreak. It means you hold an accurate model of what’s happening rather than a generalized one. There is a difference between “there is an active Ebola outbreak with real mortality” and “I am at risk of Ebola.” Both can exist at the same time. The first one is true. The second one, for most people reading this, isn’t.

Why “calm down, you’ll be fine” isn’t the answer

When people feel anxious about something like this, the worst thing a trusted source can do is wave it off. It tells the worried person that their feeling is wrong. It signals that you’re not engaging seriously with something real. And it sends them somewhere else to find answers — usually somewhere without clinical grounding.

I’ve seen this in disaster response. The communities that come through crises best are not the ones who weren’t scared. They’re the ones who had accurate information early and used it to make decisions. Fear plus facts is manageable. Fear without facts isn’t.

If the Ebola coverage is unsettling you this week, that’s not irrational. There’s a real outbreak. The vaccine that worked before doesn’t apply here. International response is more complicated because of it. All of that is true. What that feeling is telling you, if you’re willing to listen carefully, isn’t “panic.” It’s “pay attention.” And there’s something constructive to do with that.

What preparation actually looks like

When I work with families on emergency readiness, I start with the same question: what does your household do when the system doesn’t work?

That question applies whether the disruption is an active outbreak, a hurricane, a supply chain failure, or a routine illness that hits on a Sunday when urgent care is closed. The households that navigate disruptions best aren’t the ones who panicked when headlines got scary. They’re the ones who had already built a baseline: medications on hand, documentation in order, a clinical resource they trust.

Ebola doesn’t directly threaten most American households right now. What does threaten households — every week, quietly, without a news cycle behind it — is the absence of preparation for disruptions that are coming regardless of what’s happening in the DRC.

That’s what I think about when I see a headline like this. Not fear. Inventory.

If you want to build that baseline with clinical oversight from a team that takes this seriously, Jase Response is where we do that work. Appropriate medical preparation — before you need it.

👉 Support Jase Response


Aaron Asay, PA-C, DMSc, is a physician assistant with 25+ years of frontline emergency response experience, former firefighter and paramedic, military disaster rescue officer, and founder of Jase Response.

Lifesaving Solutions

Everyone should be empowered to care for themselves and their loved ones during the unexpected. Check out our recent lifesaving products today.

Recent Posts

Keeping you informed and safe.

For Clinicians | Doxycycline Uses

For Clinicians | Doxycycline Uses

For Clinicians | Doxycycline Uses Lyme Prophylaxis, Malaria Prevention, Acne, and the Doxy-PEP Debate By Dr. Jamie Wilkey, PharmD — Director of Clinical Strategy, JaseMedically reviewed and edited by Kristen Carpenter, PA-C We're continuing our series on the...

read more
For Clinicians | The Family Emergency Plan Checklist

For Clinicians | The Family Emergency Plan Checklist

For Clinicians | The Family Emergency Plan Checklist The Medical Layer Most Plans Miss By Dr. Jamie Wilkey, PharmD — Director of Clinical Strategy, JaseMedically reviewed and edited by Aaron Asay, PA-C, DMSc, FIBODM, FAWM When disaster strikes, medical personnel in a...

read more
Food Poisoning vs. Stomach Infection

Food Poisoning vs. Stomach Infection

Food Poisoning vs. Stomach Infection Three Different Stomach Bugs. Three Different Answers to 'Do I Need Antibiotics? By Cayla McGrath 'Food poisoning,' 'stomach flu,' and 'stomach infection' get treated as essentially the same thing — and the prescription question...

read more
For Clinicians | Food Poisoning, Stomach Flu, or H. Pylori

For Clinicians | Food Poisoning, Stomach Flu, or H. Pylori

For Clinicians | Food Poisoning, Stomach Flu, or H. Pylori Do You Actually Need Antibiotics? By Dr. Jamie Wilkey, PharmD — Director of Clinical Strategy, JaseMedically reviewed by Kristen Carpenter, PA-C — Clinical Advisory Board Member Three patients, same complaint....

read more

Join Our Newsletter

Our mission is to help you be more medically prepared. Join our newsletter and follow us on social media for health and safety tips each week!

The FDA’s BPC-157 Briefing Document Says Less Than It Sounds Like

No, FDA Isn’t Banning BPC-157

The July 2026 briefing document says less than it sounds like it says

By Dr. Shawn Rowland, MD, Founder and CEO of Jase

Every week a patient brings up BPC-157. Sometimes it’s a gym client asking about tendon healing, sometimes it’s someone who found it through a peptide forum for gut issues. So when FDA posted a nearly 70-page briefing document ahead of the Pharmacy Compounding Advisory Committee meeting on July 23 and 24, 2026, I read the whole thing.¹ It’s worth unpacking, because the headline version that will circulate (“FDA moves to ban BPC-157”) is not actually what the document says.

It also helps to know BPC-157 was not singled out. FDA reviewed seven peptides at this meeting, and its scientists recommended against adding all seven to the compounding list.² This is a document about how thin the evidence base is across a whole category, not a verdict aimed at one molecule.

What’s actually being decided

Two compounders, Wells Pharmacy Network and LDT Health Solutions, nominated BPC-157 (and its acetate salt form) for the 503A Bulks List, the list of substances a compounding pharmacy can legally use to make individualized prescriptions. Both nominations were withdrawn. FDA decided to evaluate the peptide anyway, on its own initiative, but narrowed the efficacy review to one specific use: ulcerative colitis. That narrowing matters. The agency explicitly did not evaluate BPC-157 for tendonitis, Crohn’s, or Celiac disease, because the nominators never submitted enough information for those uses to be reviewed at all.¹ So the efficacy question in front of the committee is about ulcerative colitis, not about everything patients are actually using the peptide for.

This is also not happening in a vacuum. BPC-157 spent two years on FDA’s Category 2 list of substances that raise significant safety concerns, came off that list in April 2026 as part of a broader reconsideration of restricted peptides, and now lands in front of this committee.³ The July meeting is one technical step inside a much larger, very public back-and-forth over peptide access.

What FDA actually found

Strip away the regulatory language and the case is this. There is no USP monograph for BPC-157 in either form. The two nominators couldn’t even agree with their own paperwork on whether they were nominating the free base or the acetate salt, and their certificates of analysis didn’t match what they wrote in the nomination¹. For efficacy, FDA found exactly one trial in UC patients, a 53 person rectal enema study that exists only as a conference abstract, with no real detail on inclusion criteria or statistical methods, and no statistically significant benefit over placebo¹. For human safety, the FAERS database returned three case reports, all involving injectable BPC-157. One was confounded by a second peptide the patient was also injecting, one could not be interpreted because almost no information was reported, and one involved a product that also contained TB-500, where the reaction returned when the patient restarted it but could not be pinned to either peptide.¹ Nobody has run a human pharmacokinetic study for oral, subcutaneous, nasal, or transdermal delivery, despite those being the four routes patients are actually using¹.

On the animal side, the picture is more reassuring than the headline suggests. BPC-157 wasn’t mutagenic in Ames assays, didn’t cause birth defects in pregnant rats at any tested dose, and produced no clearly drug-attributable serious events in the small human record that exists.The toxicology read is closer to “we don’t have enough information to rule out risk” than “we found a dangerous compound.”

Where I land on this

I built a telemedicine practice around the idea that patients deserve more access to care, not less. So I want to be precise about where I agree with FDA and where I do not.

The part FDA gets right is the quality question. A substance sold under one name while carrying two different chemical identities, with no monograph and no agreed impurity-testing standard, is a real problem, especially for injectable and nasal products where endotoxin and aggregation risk are genuine. FDA’s recommendation rests mostly here: its scientists call BPC-157 “not well-characterized” and point to missing data on impurities, aggregates, and sterility, not to a finding that the peptide failed.¹ That is a legitimate concern, and I am not going to pretend otherwise.

Here is where I part ways. A quality problem calls for a higher quality bar, not for pushing the substance out of the one channel where quality can be controlled. BPC-157 has been studied since 1993⁴ and has millions of views across social media and peptide forums. That demand is not waiting on a committee vote.

If BPC-157 comes off the 503A list, that demand doesn’t disappear. It moves to the channels FDA isn’t even discussing in this document: direct-to-consumer peptide sellers shipping vials labeled “research use only,” med spas with no physician oversight, and telehealth operations cutting corners on the very COA and purity testing that legitimate compounders are required to provide. The exact impurity and aggregation risk the agency is worried about gets worse, not better, once you push the substance out of a regulated pharmacy and into a supply chain with zero accountability.

If the goal is patient safety, the better path is tightening the quality bar inside the regulated channel: require validated impurity testing, require a real CoA before listing approval, and build a post-market surveillance mechanism through the outsourcing facility reporting structure that already exists. Pulling the substance off the list without a parallel path for legitimate use doesn’t solve the underlying problem. It just moves it somewhere nobody is watching.

What patients and prescribers can actually do:

The committee meets July 23 and 24. If you want your experience on the record, be clear-eyed about the calendar. The window to register to speak at the meeting has closed, and the deadline for written comments to reach the committee before it votes has passed. What is still open: FDA is accepting written comments through July 22 under docket FDA-2025-N-6895 at regulations.gov, and those comments go to the agency as it finalizes its decision after the meeting.⁵ A committee recommendation is not a final rule. The decision is not closed yet, and prescribers with real case experience, along with patients treated through licensed pharmacies, are exactly the input this record is thin on.


Sources:

  1. FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026 (BPC-157 free base and acetate). Docket FDA-2025-N-6895. https://www.fda.gov/media/193343/download
  2. FDA, 2026 Meeting Materials, Pharmacy Compounding Advisory Committee. https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/2026-meeting-materials-pharmacy-compounding-advisory-committee
  3. FDA interim policy on compounding using bulk drug substances; removal of BPC-157 from the Category 2 list, April 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  4. Sikiric P, et al. First description of BPC-157 (gastric pentadecapeptide), 1993; subsequent preclinical literature 1993-2024.
  5. Federal Register, Pharmacy Compounding Advisory Committee; Notice of Meeting; docket FDA-2025-N-6895 (comment and registration deadlines). https://www.federalregister.gov/documents/2026/04/16/2026-07361/

 

Lifesaving Solutions

Everyone should be empowered to care for themselves and their loved ones during the unexpected. Check out our recent lifesaving products today.

Recent Posts

Keeping you informed and safe.

For Clinicians | Doxycycline Uses

For Clinicians | Doxycycline Uses

For Clinicians | Doxycycline Uses Lyme Prophylaxis, Malaria Prevention, Acne, and the Doxy-PEP Debate By Dr. Jamie Wilkey, PharmD — Director of Clinical Strategy, JaseMedically reviewed and edited by Kristen Carpenter, PA-C We're continuing our series on the...

read more
For Clinicians | The Family Emergency Plan Checklist

For Clinicians | The Family Emergency Plan Checklist

For Clinicians | The Family Emergency Plan Checklist The Medical Layer Most Plans Miss By Dr. Jamie Wilkey, PharmD — Director of Clinical Strategy, JaseMedically reviewed and edited by Aaron Asay, PA-C, DMSc, FIBODM, FAWM When disaster strikes, medical personnel in a...

read more
Food Poisoning vs. Stomach Infection

Food Poisoning vs. Stomach Infection

Food Poisoning vs. Stomach Infection Three Different Stomach Bugs. Three Different Answers to 'Do I Need Antibiotics? By Cayla McGrath 'Food poisoning,' 'stomach flu,' and 'stomach infection' get treated as essentially the same thing — and the prescription question...

read more
For Clinicians | Food Poisoning, Stomach Flu, or H. Pylori

For Clinicians | Food Poisoning, Stomach Flu, or H. Pylori

For Clinicians | Food Poisoning, Stomach Flu, or H. Pylori Do You Actually Need Antibiotics? By Dr. Jamie Wilkey, PharmD — Director of Clinical Strategy, JaseMedically reviewed by Kristen Carpenter, PA-C — Clinical Advisory Board Member Three patients, same complaint....

read more

Join Our Newsletter

Our mission is to help you be more medically prepared. Join our newsletter and follow us on social media for health and safety tips each week!

For Clinicians | How to Talk to Patients About Ebola (and the Next Scary Headline)

For Clinicians | How to Talk to Patients About Ebola

(and the Next Scary Headline)

By Dr. Jamie Wilkey, PharmD — Director of Clinical Strategy, Jase
Edited and approved by Kristen Carpenter, PA-C — Clinical Advisory Board Member

The question we’re getting this week (or asking ourselves inside every time we hear about Ebola on the news) is, “Is this going to be like COVID?”

WHO declared a public health emergency in May. JFK is screening flights from affected countries. The strain driving the 2026 outbreak in the DRC, Bundibugyo virus, has no licensed vaccine and no specific treatment for it. CDC currently assesses the risk to Americans as low.

That is the news. The harder part of the job, the part that lands on us is the exam-room conversation that comes after it. Today we’re covering what the 2026 outbreak actually is, what CDC is and isn’t saying about US risk, and moves that actually work when a patient brings a big headline like this into the room.


How is the 2026 outbreak different from past Ebola outbreaks?

The vaccine. Ervebo, licensed in the US in 2019, is the vaccine our patients are picturing when they hear the word.¹ It works against Zaire ebolavirus. It does not work against Bundibugyo, the species driving the 2026 DRC outbreak.² Bundibugyo has been responsible for two earlier outbreaks (Uganda 2007, DRC 2012), neither of which got much US media coverage. There is no licensed vaccine for it, no licensed monoclonal antibody product, no specific antiviral.³

CDC’s US risk assessment is low, and the wording matters: travel from an affected country is not by itself an epidemiologic risk factor.⁴ The exposure pathway is direct contact with the body fluids of a symptomatic person, or with surfaces and objects contaminated by them.


The hype and virality we weren’t trained for

That’s the part our professional education didn’t cover. We were trained how to communicate diagnosis, treatment, and informed consent. We were not really trained in bedside risk communication. And the patient sitting across from us is being inundated every day with scary headlines and scary messages across every news platform and social feed they touch.

I don’t think patients are flooding doctors’ offices this week asking about Ebola. The reason this matters is that the question will come up everywhere else. Formally in the exam room, sometimes. Informally with your staff. And at the neighborhood barbecue this weekend, when somebody figures out you work in healthcare and wants to know what you think.

Peter Sandman has been working in risk communication for public health for forty years. He calls this Risk = Hazard + Outrage.⁵ Hazard is the actual probability of harm. Outrage is how upsetting it feels. High-hazard, low-outrage is the smoker who isn’t worried about lung cancer. Low-hazard, high-outrage is Ebola in the news cycle, which is exactly the conversation we’re walking into this week.

Sandman is explicit on what doesn’t work: telling an outraged person to calm down. It reads as dismissive. It tells the worried person their feeling is wrong and their trusted source isn’t taking them seriously. The next time something actually matters, that patient calls someone else.

Most of us default to “you’re fine, there’s almost no risk here, where you are, so don’t worry about it.” Patients notice. And when we don’t give them an answer they can actually carry home, they go to the internet for one. Most of us know in our hearts that they are fine. Of all the things to worry about in life right now, this isn’t one of them. We just don’t have the language ready to walk them all the way there.


Three moves that actually work

These come out of the canonical risk communication literature: the EPA’s Seven Cardinal Rules,⁶ Sandman’s outrage management work, and forty years of public health practice.

  • Acknowledge the emotion before the fact.

The instinct is to lead with the data. “The actual risk to you is very low.” It’s correct. It lands flat. The patient came in scared and you skipped the part where you noticed. A sentence you could say in the room: “That headline is hard to look at. A lot of people I’m talking to this week have the same question. Let me tell you what I’m watching.” Same move at the barbecue: “Yeah, the news on this one is pretty unsettling. Here’s what I’m actually paying attention to.”

  • Admit uncertainty plainly.

The “confident” sentence accidentally sounds dismissive. The plainer sentence is shorter and lands better. “I don’t know yet how the international response will play out, and the strain in this outbreak doesn’t have a licensed vaccine. What I do know is that the exposure pathway is narrow, and we can talk through it.” Naming what we don’t know doesn’t undermine credibility. It builds it.

  • Redirect from “travel equals risk” to the actual exposure pathway.

CDC is explicit: travel from an affected country is not by itself an epidemiologic risk factor.⁷ Exposure is direct contact with the body fluids of a symptomatic person, or with surfaces and objects contaminated by them. Healthcare workers, burial team members, lab workers, and household caregivers carry the real risk. A casual co-worker, a fellow plane passenger, a kid in your kid’s class, a parent who traveled: none of them fit the actual pathway. Walking someone through it moves them from generalized worry to a specific mental model they can act on.


Appropriate medical preparation

Headline anxiety isn’t separate from the rest of medical preparedness. It’s the entry point to it. The patient asking about Ebola is often the same patient who has already noticed that pharmacies run out, that supply chains break, that the last news cycle changed how their household thinks about being ready for the next one. Dismissing the worry sends them looking for answers somewhere less responsible. Engaging it opens the next conversation: what does being prepared for their unique circumstances actually look like for them?

Appropriate medical preparation is the category we are building. The calibrated clinical voice is one layer of it. The structural layer is the chronic med supply they have on the shelf, the documented list they can hand to anyone, and the contingency meds for common conditions that don’t wait for normal pharmacy hours. None of this replaces primary care. It complements it. The households already paying attention to where the system is thin get there first; the rest follow when they have to.

Charting the grey area in public

If you’d rather hand patients a clinical reference than improvise an answer between rooms, send them our way at jase.com. We are publishing the framework we use, where we draw the lines, and what we are still working through. Public knowledge gets better when clinicians chart the grey area in public instead of letting the internet do it.


The bottom line

There will be another headline soon. The skill we are naming today is the one that travels: acknowledge the emotion, admit what we don’t know, redirect to the actual pathway. The structural preparation travels too: your patients’ med supply and their contingency kit. Both are appropriate medical preparation. Reply with the headline you want explained next without the panic. We’re building that library on purpose.


Sources

  1. U.S. Food and Drug Administration. ERVEBO. https://www.fda.gov/vaccines-blood-biologics/ervebo
  2. Centers for Disease Control and Prevention. About the Current Ebola Outbreak. https://www.cdc.gov/ebola/situation-summary/about-current-outbreak.html
  3. World Health Organization. Epidemic of Ebola Disease caused by Bundibugyo virus in the Democratic Republic of the Congo and Uganda determined a public health emergency of international concern. 17 May 2026. https://www.who.int/news/item/17-05-2026-epidemic-of-ebola-disease-in-the-democratic-republic-of-the-congo-and-uganda-determined-a-public-health-emergency-of-international-concern
  4. Centers for Disease Control and Prevention. Interim Guidance for Public Health Assessment and Management of Travelers from Countries Affected by the 2026 Ebola Outbreak. https://www.cdc.gov/ebola/php/emergency-guidance/index.html
  5. Peter M. Sandman. Outrage Management Index. https://www.psandman.com/index-OM.htm
  6. U.S. Environmental Protection Agency. Covello VT, Allen FW. Seven Cardinal Rules of Risk Communication. Office of Policy Analysis, 1988. https://archive.epa.gov/care/web/pdf/7_cardinal_rules.pdf
  7. Centers for Disease Control and Prevention. Interim Guidance for Public Health Assessment and Management of Travelers from Countries Affected by the 2026 Ebola Outbreak. https://www.cdc.gov/ebola/php/emergency-guidance/index.html

 

Lifesaving Solutions

Everyone should be empowered to care for themselves and their loved ones during the unexpected. Check out our recent lifesaving products today.

Recent Posts

Keeping you informed and safe.

For Clinicians | Doxycycline Uses

For Clinicians | Doxycycline Uses

For Clinicians | Doxycycline Uses Lyme Prophylaxis, Malaria Prevention, Acne, and the Doxy-PEP Debate By Dr. Jamie Wilkey, PharmD — Director of Clinical Strategy, JaseMedically reviewed and edited by Kristen Carpenter, PA-C We're continuing our series on the...

read more
For Clinicians | The Family Emergency Plan Checklist

For Clinicians | The Family Emergency Plan Checklist

For Clinicians | The Family Emergency Plan Checklist The Medical Layer Most Plans Miss By Dr. Jamie Wilkey, PharmD — Director of Clinical Strategy, JaseMedically reviewed and edited by Aaron Asay, PA-C, DMSc, FIBODM, FAWM When disaster strikes, medical personnel in a...

read more
Food Poisoning vs. Stomach Infection

Food Poisoning vs. Stomach Infection

Food Poisoning vs. Stomach Infection Three Different Stomach Bugs. Three Different Answers to 'Do I Need Antibiotics? By Cayla McGrath 'Food poisoning,' 'stomach flu,' and 'stomach infection' get treated as essentially the same thing — and the prescription question...

read more
For Clinicians | Food Poisoning, Stomach Flu, or H. Pylori

For Clinicians | Food Poisoning, Stomach Flu, or H. Pylori

For Clinicians | Food Poisoning, Stomach Flu, or H. Pylori Do You Actually Need Antibiotics? By Dr. Jamie Wilkey, PharmD — Director of Clinical Strategy, JaseMedically reviewed by Kristen Carpenter, PA-C — Clinical Advisory Board Member Three patients, same complaint....

read more

Join Our Newsletter

Our mission is to help you be more medically prepared. Join our newsletter and follow us on social media for health and safety tips each week!

The War Nobody Prepared For: How the Iran Conflict Is Threatening Your Medicine Cabinet

*By the Jase Medical Clinical team*

Most Americans think of war as something that happens somewhere else, visible mainly through a screen. The Iran conflict has found its way into something far more intimate: the medicine bottles in your bathroom cabinet.Since Iran closed the Strait of Hormuz in March 2026, a quiet crisis has been unfolding in America’s pharmaceutical supply chain.

Most families haven’t felt it yet.
But they will.


The Hidden Anatomy of Your Prescription

The pills we Americans swallow are rarely wholly American-made. The US has no domestic source for more than 80% of essential medicine APIs¹, and the vast majority of what we do import comes from India and China. You’re saying, ok, that’s fine, because everything in America is made in China. Where it matters is that those ingredients travel to manufacturing plants via container ships that, until recently, transited the Persian Gulf which is where the Strait of Hormuz is located.

The Strait of Hormuz carries approximately 20% of the world’s oil and liquefied natural gas². Petrochemicals are also the basis for the plastic packaging on prescription bottles, the chemical precursors that go into the medications themselves, the manufacturing inputs upstream of both, and the fuel that moves all of it around the world. When the strait closes, the ripple effect doesn’t stop at the gas pump. Those ripples really rock the pharmacy world.

Sir Jim Mackey, NHS England’s chief executive, publicly said he is “really worried” about pharmaceutical supply chain challenges³, and the US faces the same exposure.

CNBC reported in March that the Hormuz closure puts America’s generic drug prescriptions at measurable risk⁴. And just skipping this shipping lane doesn’t solve our supply chain problems either: more than half of biopharmaceuticals ship by air cargo⁵. With fuel prices surging and Middle East flight routes canceled, even drugs that don’t originate near the Gulf are getting more expensive to move.


What Does This Mean For You?

The medications most at risk are the ones you’d least want to run out of: generic antibiotics, blood pressure medications, diabetes drugs, thyroid hormones, psychiatric medications, and pain management drugs. These are the workhorses of American healthcare and staples in your own medicine cabinet. Cheap, prescribed daily, ubiquitous on every formulary, and almost entirely dependent on an intact global supply chain.

In a prolonged disruption, “just-in-time” pharmacy inventory models fail. Retail pharmacies typically hold only 2-4 weeks of stock⁶….and that’s without a run on supplies if people start feeling desperate and asking for larger amounts. Hospitals run leaner. The federal Strategic National Stockpile was not designed for a sustained pharmaceutical supply disruption of this scale⁷ and can’t be relied upon for an entire country during a war that isn’t likely to be over very soon.

The families who feel this first are those living prescription-to-prescription, with no backup supply and no plan.


The Physician’s Honest Assessment

I’ve spent my career in emergency and family medicine. I’ve watched patients ration insulin to stretch a vial another two weeks. I’ve watched them stop antibiotics early to save a few pills for next time. I’ve watched them put off a refill on a maintenance medication they’d taken every day for ten years because the pharmacy was backordered. I’ve watched them give up entirely when the backorder stretched too long. Those were peacetime failures, inside a fully functioning supply chain.

What we’re entering now is different. Supply chain disruptions compound. Prices rise before shortages appear, which gives you a window to act if you’re paying attention.

This is a call to prepare appropriately.


What You Can Do Right Now

The most important step a family can take right now is to stop depending on the assumption that whatever you need will be available at your pharmacy next Tuesday.

That means:

  • Talk to your physician about a 90-day supply of any critical maintenance medications. Many insurance plans allow it. Ask.
  • Prioritize antibiotics in your emergency kit. Bacterial infections don’t pause for supply chain crises.
  • Understand which medications in your household are generics with overseas-sourced ingredients. (Hint: Most of them are).
  • Build a relationship with a direct-care or telehealth provider who can guide you clinically when hospitals are overwhelmed and pharmacy shelves are thin.

At Jase Medical, we built our emergency antibiotic kits around exactly this reality. A physician, a prescription, an available pharmacy, and the time to get all three aligned will not always show up together when you need them most. A JaseCase puts clinical-grade antibiotics in your hands, prescribed by a real physician and packaged with clear dosing guidance, ready before the crisis arrives. The clinical work is done before you need it.


The Bottom Line

The Iran conflict is a supply chain event and a public health event as much as a geopolitical one. Right now, while most Americans are watching the news instead of checking their medicine cabinets, there is still time to act

The window for preparation closes the day the shortage notice posts on the pharmacy website. That window is still open. Use it.

Build your medical safety net before supply chains tighten further. Visit jase.com to learn about our physician-prescribed emergency antibiotic kits and preparedness resources.


This article is for educational purposes and does not constitute medical advice. Consult a physician for diagnosis and treatment of any illness.


 

Sources:

  1. U.S. Pharmacopeia and FDA reporting: greater than 80% of active pharmaceutical ingredients for essential medicines and key therapeutic areas have no US manufacturing source. The majority of imported APIs come from India and China. https://qualitymatters.usp.org/over-half-active-pharmaceutical-ingredients-api-prescription-medicines-us-come-india-and-european
  2. U.S. Energy Information Administration, “Amid regional conflict, the Strait of Hormuz remains critical oil chokepoint” and “About one-fifth of global LNG trade flows through the Strait of Hormuz.” Approximately 20% of global petroleum liquids and 20% of global LNG trade transit the strait. https://www.eia.gov/todayinenergy/detail.php?id=65504 and https://www.eia.gov/todayinenergy/detail.php?id=65584
  3. Sir Jim Mackey, NHS England Chief Executive, public comments in late March 2026, reported by LBC. https://www.lbc.co.uk/article/nhs-england-iran-war-supplies-warning-5HjdX7J_2/
  4. CNBC, “Strait of Hormuz standoff puts supply of America’s generic drug prescriptions at risk,” March 16, 2026. https://www.cnbc.com/2026/03/16/strait-of-hormuz-closure-generic-drug-prescriptions.html
  5. IATA, Healthcare Cargo Handling & Transport: more than 50% of biopharmaceuticals move by air. https://www.iata.org/en/programs/cargo/pharma/
  6. NCPA Digest data: average retail pharmacy turns inventory 12.2 times per year (~30-day stock cycle); 2-4 weeks is a defensible range. CNBC (source #4) notes pharmaceutical distributors carry 30-60 days at a layer up. https://ncpa.org/
  7. HHS/ASPR Strategic National Stockpile, “Sustaining the Stockpile.” Built for acute large-scale public health emergencies (CBRN threats, pandemics, natural disasters), not sustained outpatient prescription disruption. The August 2025 SAPIR Executive Order separately directs ASPR to build a Strategic Active Pharmaceutical Ingredients Reserve, an explicit acknowledgment that the existing SNS does not cover this. https://aspr.hhs.gov/SNS/Pages/Sustaining-the-Stockpile.aspx

Lifesaving Solutions

Everyone should be empowered to care for themselves and their loved ones during the unexpected. Check out our recent lifesaving products today.

Recent Posts

Keeping you informed and safe.

For Clinicians | Doxycycline Uses

For Clinicians | Doxycycline Uses

For Clinicians | Doxycycline Uses Lyme Prophylaxis, Malaria Prevention, Acne, and the Doxy-PEP Debate By Dr. Jamie Wilkey, PharmD — Director of Clinical Strategy, JaseMedically reviewed and edited by Kristen Carpenter, PA-C We're continuing our series on the...

read more
For Clinicians | The Family Emergency Plan Checklist

For Clinicians | The Family Emergency Plan Checklist

For Clinicians | The Family Emergency Plan Checklist The Medical Layer Most Plans Miss By Dr. Jamie Wilkey, PharmD — Director of Clinical Strategy, JaseMedically reviewed and edited by Aaron Asay, PA-C, DMSc, FIBODM, FAWM When disaster strikes, medical personnel in a...

read more
Food Poisoning vs. Stomach Infection

Food Poisoning vs. Stomach Infection

Food Poisoning vs. Stomach Infection Three Different Stomach Bugs. Three Different Answers to 'Do I Need Antibiotics? By Cayla McGrath 'Food poisoning,' 'stomach flu,' and 'stomach infection' get treated as essentially the same thing — and the prescription question...

read more
For Clinicians | Food Poisoning, Stomach Flu, or H. Pylori

For Clinicians | Food Poisoning, Stomach Flu, or H. Pylori

For Clinicians | Food Poisoning, Stomach Flu, or H. Pylori Do You Actually Need Antibiotics? By Dr. Jamie Wilkey, PharmD — Director of Clinical Strategy, JaseMedically reviewed by Kristen Carpenter, PA-C — Clinical Advisory Board Member Three patients, same complaint....

read more

Join Our Newsletter

Our mission is to help you be more medically prepared. Join our newsletter and follow us on social media for health and safety tips each week!

Your Immune System Can Fight Cancer

*By the Jase Medical Clinical team*

For decades, the dream in oncology has been simple and audacious: teach your own immune system to hunt cancer. Not poison it with chemotherapy. Not burn it with radiation. Train your body’s existing defenses to do what they were arguably designed to do — identify and destroy abnormal cells.

That dream is moving from the lab bench to clinical reality faster than most people realize. And what’s emerging isn’t just exciting for cancer patients — it’s a fundamental rethinking of how we relate to our own biology.


The Tumor That Vanished

In March 2026, researchers published results that stopped the oncology world in its tracks. A redesigned immunotherapy approach — injecting a modified CD40 agonist antibody directly into a single tumor — triggered immune responses that eliminated cancer throughout the body.

One injection site. Cancer vanishing elsewhere.

This isn’t the first time researchers have attempted localized immunotherapy. What’s different now is the engineering. Scientists redesigned the antibody structure for greater potency and changed its delivery to maximize the immune cascade effect. Early results describe the response as “striking” — after years of disappointing outcomes with predecessor compounds.

The implications are profound. Rather than flooding the entire body with systemic immunotherapy and its significant toxicities, you prime the immune system at one location — and let it do the rest. Less collateral damage. Potentially far greater precision.


Your Diet May Be a Cancer-Fighting Tool

Just last week, another study added a quieter but equally important piece to the puzzle. Researchers found that zeaxanthin — a carotenoid found naturally in eggs, leafy greens, and orange peppers — slowed tumor growth in mouse models. More importantly, the effect became dramatically more pronounced when combined with immune checkpoint inhibitors, the same class of drugs that has already transformed treatment for melanoma and lung cancer.

In other words: a common dietary nutrient appears to amplify one of the most powerful classes of cancer therapy we currently have.

This is not a cure. Mouse studies don’t always translate directly to humans. But this is exactly the kind of signal that deserves serious attention — particularly because zeaxanthin is safe, inexpensive, and widely available. For health-conscious families, it’s a compelling reminder that what’s on your plate is not neutral. Diet is medicine.


Reprogramming Immune Cells — Inside the Body

Perhaps the most technically remarkable development comes from scientists who have found a way to reprogram cancer-fighting immune cells directly inside the body — no extraction, no lab, no weeks of manufacturing.

Current CAR-T cell therapy — one of the most promising cancer treatments in existence — requires exactly that laborious process: extract T-cells from the patient, genetically modify them over weeks in specialized facilities, then reinfuse them. It’s effective for certain blood cancers. It’s also extraordinarily expensive and logistically out of reach for most of the world.

The new in-body reprogramming approach uses targeted delivery mechanisms to trigger immune cell modification *in vivo* — inside you, in real time. Early results show rapid tumor clearance. If this technology scales, it could fundamentally democratize access to immunotherapy beyond major cancer centers.


What This Means for You — Right Now

You don’t need to wait for phase three trials to take these signals seriously. Here’s what the evidence already supports.

Eat your carotenoids. Eggs, kale, corn, orange peppers, and spinach are all rich in zeaxanthin and lutein. If immune checkpoint inhibitors are part of your treatment picture, talk to your oncologist about the emerging dietary synergy research.

Know your immune baseline. Chronic inflammation, metabolic dysfunction, and nutrient deficiencies all blunt immune response. The same immune system these researchers are working to harness is the one protecting you every day.

Don’t dismiss early-stage research. The CD40 agonist approach looked impossible a decade ago. In-body CAR-T reprogramming sounded like science fiction five years ago. The pace of translation from bench to bedside is accelerating.


The Preparedness Angle

At Jase Medical, we often talk about preparedness in the context of acute emergencies — the antibiotic kit for when a pharmacy isn’t available, the medical supplies for when healthcare infrastructure fails. But genuine preparedness extends to your long-term health resilience.

The families we serve ask hard questions: What if I or someone I love faces a serious diagnosis in a disrupted healthcare environment? What does it mean to be truly healthy — not just symptom-free? These immunotherapy breakthroughs belong in that conversation. Understanding your immune system is foundational — and it’s exactly the kind of physician-graded intelligence we’re committed to delivering.


Take the Next Step

If this kind of health intelligence matters to your family, subscribe to the Jase Medical newsletter at Jase.com for regular updates at the intersection of cutting-edge medicine and practical preparedness.

And if you haven’t yet built your family’s medical foundation, explore the JaseCase — because the best time to prepare is always before you need it.


This article is for educational purposes and does not constitute medical advice. Consult a physician for diagnosis and treatment of any illness.


Learn more about Jase Medical’s emergency preparedness kits and other medication solutions at jase.com

*Sources: ScienceDaily (March 15, 2026 — CD40 agonist localized immunotherapy); ScienceDaily (April 10, 2026 — zeaxanthin + immune checkpoint inhibitors); SciTechDaily (in-body immune cell reprogramming, 2026)*

Lifesaving Solutions

Everyone should be empowered to care for themselves and their loved ones during the unexpected. Check out our recent lifesaving products today.

Recent Posts

Keeping you informed and safe.

For Clinicians | Doxycycline Uses

For Clinicians | Doxycycline Uses

For Clinicians | Doxycycline Uses Lyme Prophylaxis, Malaria Prevention, Acne, and the Doxy-PEP Debate By Dr. Jamie Wilkey, PharmD — Director of Clinical Strategy, JaseMedically reviewed and edited by Kristen Carpenter, PA-C We're continuing our series on the...

read more
For Clinicians | The Family Emergency Plan Checklist

For Clinicians | The Family Emergency Plan Checklist

For Clinicians | The Family Emergency Plan Checklist The Medical Layer Most Plans Miss By Dr. Jamie Wilkey, PharmD — Director of Clinical Strategy, JaseMedically reviewed and edited by Aaron Asay, PA-C, DMSc, FIBODM, FAWM When disaster strikes, medical personnel in a...

read more
Food Poisoning vs. Stomach Infection

Food Poisoning vs. Stomach Infection

Food Poisoning vs. Stomach Infection Three Different Stomach Bugs. Three Different Answers to 'Do I Need Antibiotics? By Cayla McGrath 'Food poisoning,' 'stomach flu,' and 'stomach infection' get treated as essentially the same thing — and the prescription question...

read more
For Clinicians | Food Poisoning, Stomach Flu, or H. Pylori

For Clinicians | Food Poisoning, Stomach Flu, or H. Pylori

For Clinicians | Food Poisoning, Stomach Flu, or H. Pylori Do You Actually Need Antibiotics? By Dr. Jamie Wilkey, PharmD — Director of Clinical Strategy, JaseMedically reviewed by Kristen Carpenter, PA-C — Clinical Advisory Board Member Three patients, same complaint....

read more

Join Our Newsletter

Our mission is to help you be more medically prepared. Join our newsletter and follow us on social media for health and safety tips each week!

The 2026 Tick Surge Is Already Here. And It’s Worse Than Doctors Predicted.

*By the Jase Medical Clinical team*

I want to tell you something that caught my attention as a physician before it caught my attention as a CEO.

A few weeks ago I was reading through case reports from colleagues in the Northeast. Family docs, internists, infectious disease specialists. The pattern was impossible to ignore. They’re seeing tick-borne illness earlier in the year, in places they’ve never seen it, in patients who had no idea they were at risk. One physician in Vermont told me he treated his first Lyme case of the year in February.

February.

That’s not a talking point. That’s a clinical data point. And it tells you everything you need to know about where we are headed this spring and summer.


What’s Actually Happening

Tick populations have been expanding geographically for over a decade. Milder winters. Shifting wildlife corridors. More human activity in tick-dense areas. None of that is new. What is new — what makes 2026 different — is that the species carrying the most dangerous pathogens have now established permanent populations in regions that were considered safe as recently as five years ago.

The black-legged tick, Ixodes scapularis — the one responsible for Lyme disease — is not a visitor anymore in places like the upper Midwest and northern New England. It lives there now. And it’s active earlier in the spring and later into the fall, which means the old “May through August” tick season guidance is increasingly meaningless.

Physicians in northern states are treating tick-borne illness before the snow is off the ground.


Four Diseases, One Vulnerability

Most people hear “tick bite” and think Lyme disease. That’s understandable. Lyme is the most common tick-borne illness in the US, with over 476,000 cases diagnosed annually. The classic bullseye rash, the flu-like onset, the joint pain and neurological complications that follow when treatment is delayed — it’s serious. But it’s not the whole picture.

A single tick bite can transmit any of four major bacterial infections. Each one carries real consequences.

Lyme Disease (Borrelia burgdorferi). First-stage symptoms can look like a bad flu. Left untreated, it becomes something far worse — joint destruction, neurological damage, cardiac involvement. Early treatment changes the trajectory completely.

Anaplasmosis (Anaplasma phagocytophilum). Spread by the same tick as Lyme. Sudden fever, crushing headache, muscle pain. Gets misdiagnosed as flu constantly. In immunocompromised patients, it can progress to respiratory failure and organ damage.

Ehrlichiosis (Ehrlichia chaffeensis). Spread primarily by the lone star tick, whose range has pushed significantly into the Northeast. Fever, fatigue, dangerously low platelet and white blood cell counts. The mortality rate for untreated ehrlichiosis is meaningfully higher than Lyme.

Rocky Mountain Spotted Fever (Rickettsia rickettsii). The name is misleading — RMSF now occurs across much of the continental US. It is the deadliest tick-borne disease in North America. It can kill within days of symptom onset, and the classic spotted rash often shows up late, after the treatment window has already narrowed.


Here’s the Part That Matters

All four of those infections respond to the same antibiotic: doxycycline.

Doxycycline is a broad-spectrum tetracycline with exceptional activity against the intracellular bacteria behind all four diseases. For Lyme, it’s first-line treatment in adults and children over eight. For anaplasmosis, ehrlichiosis, and RMSF, it’s not just first-line — it’s the only reliably effective option.  We supply it in the base JaseCase for a reason. Everyone should have this on hand, just in case.

The CDC and the Infectious Diseases Society of America both recommend initiating doxycycline empirically — based on clinical suspicion alone, before lab results come back — when tick-borne illness is suspected. That recommendation exists because the organisms causing these diseases don’t wait for a confirmation number from the lab. And in the case of RMSF, delaying treatment while waiting on results is directly associated with higher mortality.

As a physician, that’s the piece I need you to understand. The science here is not ambiguous. Early doxycycline changes outcomes.


The Gap That Keeps Me Up at Night

Think about where most people encounter ticks. Hiking trails. Campgrounds. The backyard of a cabin two hours from the nearest urgent care. Even in suburban settings, the timeline from tick bite to symptom onset to physician visit to filled prescription can stretch across days. In serious tick-borne illness — particularly RMSF — those days are the difference between an outpatient course of antibiotics and a hospital bed.

This is the problem I built Jase Medical to solve. Not the theoretical version. The real one. The version where a family on a camping trip pulls a tick off their kid and has no way to act on what they know until Monday morning.

A supply of physician-prescribed doxycycline in your emergency medical kit means you’re not waiting on the system to catch up with the biology. You’re prepared to act when it matters.


What to Do Right Now

Start with prevention. Use EPA-registered repellents — DEET at 20% or higher, picaridin, or permethrin-treated clothing. Do full-body tick checks after any time spent outdoors. Shower within two hours of coming inside. Check your pets; they carry ticks into the home more often than people realize.

Know the warning signs. Unexplained fever with headache and muscle aches after outdoor activity. Any rash, especially one that’s spreading or has a bullseye pattern. If you see those, mention tick exposure to your physician immediately — don’t wait for someone to ask.

Close the gap. Talk to a Jase Medical physician about whether doxycycline and other emergency antibiotics belong in your family’s kit. Don’t wait for a tick-borne illness to find out you weren’t ready.


The 2026 tick surge is not hypothetical. It’s already underway. The physicians sounding the alarm are watching their patient panels and seeing the numbers climb in real time.

The good news is that the single most important medication for treating all four major tick-borne diseases is well understood, widely available, and something you can have on hand before you ever need it.

Be ready before you need to be.

Build Your Emergency Medical Kit with Jase Medical →


This article is for educational purposes and does not constitute medical advice. Consult a physician for diagnosis and treatment of any illness.


Learn more about Jase Medical’s emergency preparedness kits and other medication solutions at jase.com

Lifesaving Solutions

Everyone should be empowered to care for themselves and their loved ones during the unexpected. Check out our recent lifesaving products today.

Recent Posts

Keeping you informed and safe.

For Clinicians | Doxycycline Uses

For Clinicians | Doxycycline Uses

For Clinicians | Doxycycline Uses Lyme Prophylaxis, Malaria Prevention, Acne, and the Doxy-PEP Debate By Dr. Jamie Wilkey, PharmD — Director of Clinical Strategy, JaseMedically reviewed and edited by Kristen Carpenter, PA-C We're continuing our series on the...

read more
For Clinicians | The Family Emergency Plan Checklist

For Clinicians | The Family Emergency Plan Checklist

For Clinicians | The Family Emergency Plan Checklist The Medical Layer Most Plans Miss By Dr. Jamie Wilkey, PharmD — Director of Clinical Strategy, JaseMedically reviewed and edited by Aaron Asay, PA-C, DMSc, FIBODM, FAWM When disaster strikes, medical personnel in a...

read more
Food Poisoning vs. Stomach Infection

Food Poisoning vs. Stomach Infection

Food Poisoning vs. Stomach Infection Three Different Stomach Bugs. Three Different Answers to 'Do I Need Antibiotics? By Cayla McGrath 'Food poisoning,' 'stomach flu,' and 'stomach infection' get treated as essentially the same thing — and the prescription question...

read more
For Clinicians | Food Poisoning, Stomach Flu, or H. Pylori

For Clinicians | Food Poisoning, Stomach Flu, or H. Pylori

For Clinicians | Food Poisoning, Stomach Flu, or H. Pylori Do You Actually Need Antibiotics? By Dr. Jamie Wilkey, PharmD — Director of Clinical Strategy, JaseMedically reviewed by Kristen Carpenter, PA-C — Clinical Advisory Board Member Three patients, same complaint....

read more

Join Our Newsletter

Our mission is to help you be more medically prepared. Join our newsletter and follow us on social media for health and safety tips each week!